1.43

1.42% 0.02

Pre-market: 1.45 0.02 +1.40%

Atai Life Sciences N V (ATAI)

Overview News Price History Option Chain Financials Discussions Forecast

Atai Life Sciences N V stock is traded at $1.43, with a volume of 1.17M. It is up +1.42% in the last 24 hours and up +3.62% over the past month. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

Previous Close:

$1.41

Open:

$1.42

24h Volume:

1.17M

Relative Volume:

0.53

Market Cap:

$277.72M

Revenue:

$314.00K

Net Income/Loss:

$-40.23M

P/E Ratio:

-5.1071

EPS:

-0.28

Net Cash Flow:

$-84.71M

1W Performance:

+2.88%

1M Performance:

+3.62%

6M Performance:

+4.38%

1Y Performance:

-25.13%

1-Day Range:

$1.38

$1.455

1-Week Range:

$1.29

$1.485

52-Week Range:

$1.03

$2.565

Atai Life Sciences N V Stock (ATAI) Company Profile

Name

Atai Life Sciences N V

Sector

Healthcare (1149)

Industry

Biotechnology (673)

Phone

49 89 2153 9035

Address

WALLSTRASSE 16, BERLIN

Employee

Twitter

Next Earnings Date

2024-12-11

Latest SEC Filings

ATAI's Discussions on Twitter

Compare ATAI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATAI Atai Life Sciences N V	1.43	277.72M	314.00K	-40.23M	-84.71M	-0.28
VRTX Vertex Pharmaceuticals Inc	421.16	111.66B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	571.36	60.56B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	532.27	38.04B	2.58B	1.06B	-1.28B	16.33
ALNY Alnylam Pharmaceuticals Inc	267.55	36.06B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	219.95	25.10B	3.81B	-644.79M	-669.77M	-6.24

Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Reiterated	H.C. Wainwright	Buy
Apr-03-24	Upgrade	Maxim Group	Hold → Buy
Nov-01-22	Initiated	Loop Capital	Buy
Nov-30-21	Initiated	Maxim Group	Buy
Nov-11-21	Initiated	ROTH Capital	Buy
Oct-18-21	Initiated	H.C. Wainwright	Buy
Sep-01-21	Initiated	Jefferies	Buy
Jul-13-21	Initiated	Berenberg	Buy
Jul-13-21	Initiated	Canaccord Genuity	Buy
Jul-13-21	Initiated	Cantor Fitzgerald	Buy
Jul-13-21	Initiated	Citigroup	Buy
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	Credit Suisse	Outperform
Jul-13-21	Initiated	RBC Capital Mkts	Sector Perform
Jul-08-21	Initiated	Aegis Capital	Buy

View All

Atai Life Sciences N V Stock (ATAI) Latest News

12:31 PM

Atai Life Sciences: Progress in Psychedelic Mental Health Treatments - TipRanks

12:31 PM

May 14, 2025

Will Atai Get A New Lease Of Life? - RTTNews

May 14, 2025

Atai Life Sciences Reports First Quarter 2025 Financial Results - marketscreener.com

May 14, 2025

ATAI Reports Significant First Quarter Revenue Growth | ATAI Sto - GuruFocus

May 14, 2025

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates - The Manila Times

May 14, 2025

May 13, 2025

Certain Options of Atai Life Sciences N.V. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com

May 13, 2025

ATAI Begins Phase 2 Study for Social Anxiety Treatment | ATAI St - GuruFocus

May 13, 2025

Atai Life Sciences Announces First Patient Dosed In Phase 2 Study Of Emp-01 For The Treatment Of Social Anxiety Disorder - marketscreener.com

May 13, 2025

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder - Yahoo

May 13, 2025

May 08, 2025

ATAI Life Sciences Repays Hercules Loan Early - TipRanks

May 08, 2025

May 06, 2025

Daily Market Movement: ATAI Life Sciences N.V (ATAI) Sees a -2.00 Decrease, Closing at 1.47 - DWinneX

May 06, 2025

May 01, 2025